Edwards Lifesciences (EW) Accumulated Expenses (2009 - 2026)

Edwards Lifesciences has reported Accumulated Expenses for 18 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 0.6% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 0.6% YoY), and the FY2025 full-year result was $1.6 billion, up 21.78% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.2 billion, down from $1.6 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $1.7 billion in Q3 2024, with the low at $739.5 million in Q3 2022.
• Average Accumulated Expenses over 5 years is $1.1 billion, with a median of $939.9 million recorded in 2023.
• Year-over-year, Accumulated Expenses soared 70.44% in 2024 and dropped 20.13% in 2025.
• Tracing EW's Accumulated Expenses over 5 years: stood at $795.0 million in 2022, then increased by 7.72% to $856.4 million in 2023, then soared by 49.74% to $1.3 billion in 2024, then increased by 21.78% to $1.6 billion in 2025, then slipped by 22.93% to $1.2 billion in 2026.
• The last three Accumulated Expenses figures came in at $1.2 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.

Peer Comparison